Related posts

TSX climbs, Wall Street slipsMarkets end week higher on soft inflationInflation data and hike fears pressure stocks
Investor Insights

This summary was created by AI, based on 2 opinions in the last 12 months.

Dexcom (DXCM-Q) has recently faced significant challenges in its financial performance, as highlighted by expert reviews. The company's last quarter was notably poor, leading to a loss of confidence among investors and analysts alike. This sentiment is compounded by the fact that the quarter results missed expectations badly, and there seems to be a lack of clarity from the management regarding the reasons behind this shortfall. Experts are particularly concerned about the transparency of the company's communication with stakeholders, which can further erode trust. As a result, investors might want to proceed with caution as the company's future outlook appears uncertain at this moment.

Consensus
Negative
Valuation
Overvalued
Similar
Insulet, PODD
DON'T BUY

Their last quarter was very bad. He lost faith.

0
DON'T BUY

Their quarter missed badly and they haven't fully explained why.

0
BUY ON WEAKNESS
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research

DXCM has been hit hard as investors fear new success of weight loss drugs will reduce demand for diabetes monitoring products. DXCM is not alone in the decline. But it is still growing, and recent comments by analysts suggest the sell off is quite overdone. It has new products on tap and is strong financially. Market share remains robust. Best Buy has started selling its products (not material on its own, but shows an expanding footprint). We would see DXCM as worth holding. Because it is 33X as large was WELL, they are hard to compare. WELL, being smaller, could potentially rise more, but comes with much more overall risk. From a safety and valuation standpoint, we would, today, prefer DXCM.
Unlock Premium - Try 5i Free

0
DON'T BUY

Does well when (sadly) diabetes is booming. The fear is that drugs develop from Novo Nordisk and Eli Lilly will cut down on diabetes. He tends to agree. Be careful here.

0
DON'T BUY
The Saudi/OPEC oil cut today

He regrets he didn't sell some of his oil holdings today. He doesn't see the price of oil moving up from here, but will move down.

0
COMMENT
Shares are expensive, but their diabetes machine is the best. Likes it, but these expensive stocks have had a hard time in this market.
0
COMMENT
They make blood sugar monitors used by diabetics. One of the best growth stocks of the last 5 years, from $60 from end-2017 to $659 last November. Since then, it's plunged to $462. Today, the company reported Q4 sales were in line and issued cautious guidance for 2022. They under-promise and over-delivered.
0
BUY
They make blood-sugar monitor for diabetics. He has long liked this. Performed well last year until Covid delayed the development in their new device which happened when the market lost interest in health stocks. But a few months ago, it started to come back. Yesterday, they reported a mixed quarter with a nice revenue beat, but small earnings miss, yet offered conservative guidance expand overseas. It fell 5% today. Likes that they're spending money to grow and their conservative nature.
0
COMMENT
The stock got overheated and has pulled back. It's up over 50% YTD. The quarter they reported in late-October was imperfect with a big earnings beat but a smaller sales beat compared to previous quarter. Their new blood sugar monitor is rolling out in only some key markets in 2021, not in all key ones until 2023. Both factors led to the stock getting hurt. Today, management guided for 15-20% growth through 2025, but fell short of expectations. The stock sold off today.
0
HOLD
Medical devices. Monitor diabetes. Recurring revenue from disposable sensors. M&A potential. Really likes the sector. Stick with it.
0
Showing 1 to 10 of 10 entries
  • «
  • 1
  • »

Dexcom(DXCM-Q) Rating

Ranking : 3 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 2

Total Signals / Votes : 2

Stockchase rating for Dexcom is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Dexcom(DXCM-Q) Frequently Asked Questions

What is Dexcom stock symbol?

Dexcom is a American stock, trading under the symbol DXCM-Q on the NASDAQ (DXCM). It is usually referred to as NASDAQ:DXCM or DXCM-Q

Is Dexcom a buy or a sell?

In the last year, 2 stock analysts published opinions about DXCM-Q. 0 analysts recommended to BUY the stock. 2 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Dexcom.

Is Dexcom a good investment or a top pick?

Dexcom was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Dexcom.

Why is Dexcom stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Dexcom worth watching?

2 stock analysts on Stockchase covered Dexcom In the last year. It is a trending stock that is worth watching.

What is Dexcom stock price?

On 2025-02-21, Dexcom (DXCM-Q) stock closed at a price of $88.75.